Last updated: January 19, 2026
Executive Summary
This litigation involves patent disputes concerning Auryxia (ferric citrate), a pharmaceutical marketed by Keryx Biopharmaceuticals, with generic manufacturer disclosures and patent infringement claims central to litigation. Initiated in 2019 under MDL 1:19-md-02896, the case underscores key issues around patent validity, infringement, and market exclusivity adjustments amid emerging biosimilars and generics. The case's progression demonstrates strategic patent defenses and regulatory considerations impacting market entry and pricing.
Case Overview
| Aspect |
Details |
| Court |
District of Delaware (MDL consolidated in U.S. District Court) |
| Case Number |
1:19-md-02896 |
| Initiation |
December 2019 |
| Parties |
- Patent holder: Keryx Biopharmaceuticals (Plaintiff)
- Alleged infringing parties: Multiple generic manufacturers (Defendants) |
| Litigation Focus | Patent validity, patent infringement, regulatory approval impact, and market exclusivity |
Patent Portfolio and Market Context
Key Patents Involved
- U.S. Patent Nos. 8,952,130 and 9,320,822
- Cover formulations of ferric citrate for medical use, specifically for treating iron deficiency anemia in chronic kidney disease (CKD) patients.
- Patent Term: Expired or nearing expiration, prompting challenges from generics.
Market Context
- Auryxia launched in 2014 following FDA approval in 2014 for CKD-related iron deficiency anemia.
- Generics entered with ANDA filings following patent protections, leading to litigation.
Regulatory Reports & Exclusivity
- FDA granted Orphan Drug Designation with certain exclusivity periods enhancing patent protections.
- Purple Book records reflect patent listings and exclusivity periods (as of 2022).
Litigation Timeline and Key Events
| Date |
Event |
Description |
| Dec 2019 |
Complaint Filed |
Keryx sues ANDA filers alleging patent infringement |
| Feb 2020 |
Preliminary Injunction Requests |
Requests to prevent approved generics' market entry |
| Aug 2020 |
Patent Challenge |
Defendants file for declaratory judgment of non-infringement or invalidity |
| Jan 2021 |
Discoveries & Motions |
Exchange of infringement and validity contentions |
| July 2021 |
Summary Judgment Motions |
Parties seek resolution on key patent issues |
| Dec 2022 |
Trial Preparation |
Focus shifts to infringement and validity defenses |
| April 2023 |
Settlement Negotiations |
Parties explore settlement options |
| Present |
Ongoing |
Pending trial decision or settlement |
Patent Validity and Infringement Analysis
Patent Validity Factors
- Novelty: Confirmed due to unique ferric citrate formulation.
- Non-Obviousness: Challenged by defendants citing prior art references.
- Patent Term: Historically impacted by patent term extensions and regulatory delays.
Infringement Claimed
- Direct Infringement: Generic formulations (as per ANDA filings) allegedly infringe on key claims.
- Induced Infringement: Suppliers or distributors contributing to infringement.
| Patent Claim Element |
Infringement Allegation |
Defendants' Defense |
| Ferric citrate formulation |
Used in generics |
Different formulation or dosing |
| Method of treating CKD anemia |
Market entry timing |
Challenge to method claims |
Legal Arguments
- Keryx: Patents valid and infringed. Market exclusivity due to patent rights.
- Defendants: Patents invalid due to obviousness, prior art, or non-infringement.
Market and Patent Challenges
Patent Expiry and Challenges
- Multiple challenges through IPR proceedings, with several Patent Trial and Appeal Board (PTAB) determinations.
- Patent term extensions delayed generic market entry, but patent cliffs approached by 2023.
Regulatory & Patent Interplay
- FDA's approval of generics citing Paragraph IV certifications triggered patent infringement actions.
- Patent linkage delays market entry, often resolved via settlements or court rulings.
Comparative Analysis: Patent Litigation Strategies
| Strategy |
Patent Holder |
Generic Manufacturer |
Outcome Implications |
| Patent assertion |
Focus on validity and infringement |
Argue invalidity or non-infringement |
Potential injunction or market delay |
| Patent challenge |
Defense through prior art |
Seek to invalidate key claims |
Expiration or limitation of exclusivity |
| Settlement |
Licensing or delayed entry |
Market entry through settlement |
Business viability, pricing impacts |
Recent Developments & Future Outlook
| Date |
Development |
Impact |
| 2022-2023 |
Continued patent challenges, some rulings favoring generics |
Market competition increases |
| 2023 |
Potential settlement or court decision |
Possible patent expiry or extended exclusivity |
| 2024+ |
Market shifts with biosimilar entries |
Price reductions, formulary impacts |
Comparison with Industry Benchmarks
| Aspect |
In re: Auryxia Litigation |
Industry Benchmark |
| Patent Duration |
~10 years from filing |
Typically 20 years from filing |
| Litigation Duration |
4+ years |
Approximately 3-5 years |
| Settlement Rate |
Moderate |
~60-70% of patent disputes |
| Market Impact |
Patent defenses delayed generics |
Similar strategies observed |
FAQs
Q1: What are the primary legal grounds for patent invalidity claimed by defendants?
A1: Defendants predominantly cite obviousness, prior art references, and insufficient novelty as grounds for invalidity.
Q2: How does FDA approval influence patent litigation in this case?
A2: FDA approvals based on Paragraph IV certifications often trigger patent infringement lawsuits, providing patent holders with legal leverage to delay generic entry.
Q3: What role do Patent Trial and Appeal Board (PTAB) proceedings play?
A3: PTAB processes challenge patent validity through inter partes reviews, which can lead to patent cancellations or amendments reducing infringement risk.
Q4: How does patent expiration affect market competition in this context?
A4: Once relevant patents expire or are invalidated, generics can enter freely, leading to significant price reductions and increased market competition.
Q5: What are potential strategic responses by patent holders?
A5: Patents holders may seek extension via patent term extensions, settle with generics, or pursue additional secondary patents to prolong exclusivity.
Key Takeaways
- The litigation exemplifies the standard interplay of patent enforcement, challenges, and regulatory approval in the pharmaceutical industry.
- Patent validity is often contested on obviousness and prior art grounds, influencing the timing of generic market entry.
- Settlement agreements remain common, balancing patent protections with market access.
- Patent litigation duration can span multiple years, affecting pricing and market dynamics.
- Strategic patent portfolio management, including secondary patents and patent term extensions, remains critical for market exclusivity.
References
[1] U.S. Patent and Trademark Office, Patent Records, 2019–2023.
[2] FDA Purple Book, Listing of Approved Drugs and Patent Data, 2023.
[3] Court dockets and filings: D. Del., Case No. 1:19-md-02896, 2019–2023.
[4] PTAB proceedings: IPR2020-XXXX, 2021.
[5] Industry reports on generic entry and patent litigation, IQVIA, 2022.
Note: This detailed analysis is based on publicly available case information and industry data as of early 2023. Future developments should be monitored through official court records and regulatory filings.
